Sugi Predict

Sugi Predict / Compounds / SCHEMBL2014365

SCHEMBL2014365

SCHEMBL2014365

C[C@@]1(F)[C@H](n2ccc(=O)[nH]c2=O)O[C@H](C(O)C(=O)c2ccccc2)[C@]1(O)C(=O)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ P2RY2 P41231 1/20 0.36
▸ P2RY4 P51582 1/20 0.36
▸ POLA1 P09884 1/20 0.34
▸ NT5E P21589 1/20 0.34
▸ DUT P33316 3/20 0.33
▸ POLB P06746 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ SLC28A1 O00337 1/20 0.31
▸ SLC28A2 O43868 1/20 0.31
▸ SLC29A1 Q99808 1/20 0.31
▸ SLC28A3 Q9HAS3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20822313 1.00 CYP3A4 (0.38) CYP3A4CYP2C9P2RY2P2RY4POLA1
SCHEMBL9221120 0.89 NT5E (0.36) CYP3A4CYP2C9P2RY2P2RY4POLA1
SCHEMBL6256517 0.89 NT5E (0.36) CYP3A4CYP2C9P2RY2P2RY4POLA1
SCHEMBL794862 0.80 P2RY2 (0.31) P2RY2P2RY4POLB
SCHEMBL30366595 0.79 ABL1 (0.45) CYP2C9NT5EPOLB
SCHEMBL1828525 0.77 P2RY2 (0.47) CYP3A4CYP2C9P2RY2P2RY4POLA1
SCHEMBL5080723 0.75 LMNA (0.36) NT5E
SCHEMBL9223581 0.75 RNASE1 (0.44) POLB
SCHEMBL5610629 0.72 RNASE1 (0.32) P2RY2
SCHEMBL5547202 0.72 SLC28A1 (0.43) CYP3A4CYP2C9P2RY2P2RY4POLA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12121529-B2 Nucleoside phosphoramidate prodrugs GILEAD SCIENCES, INC. (US) 2024-10-22 — — US disclosed
EP-2203462-B2 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS GILEAD PHARMASSET LLC (US) 2024-09-25 — — EP disclosed
US-20240139227-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS GILEAD PHARMASSET LLC 2024-05-02 — — US disclosed
EP-4282482-A2 Nucleoside phosphoramidate prodrugs Gilead Sciences, Inc. (US) 2023-11-29 — — EP disclosed
EP-2801580-B1 Nucleoside phosphoramidate prodrugs GILEAD SCIENCES INC (US) 2023-09-13 — — EP disclosed
US-11642361-B2 Nucleoside phosphoramidate prodrugs GILEAD SCIENCES, INC. (US) 2023-05-09 — — US disclosed
US-20210196741-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS GILEAD PHARMASSET LLC 2021-07-01 — — US disclosed
EP-2826784-B1 Composition comprising a HCV NS3 protease inhibitor and a phosphoramidate prodrug of 2'-deoxy-2'-fluoro-2'-C-methyluridine nucleoside GILEAD PHARMASSET LLC (US) 2019-06-26 — — EP disclosed
US-10183037-B2 Nucleoside phosphoramidate prodrugs GILEAD PHARMASSET LLC (US) 2019-01-22 — — US disclosed
WO-2018015821-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF SOFOSBUVIR OPTIMUS DRUGS (P) LIMITED (IN) 2018-01-25 — — WO disclosed
US-20140045783-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS GILEAD PHARMASSET LLC (US) 2014-02-13 — — US disclosed
US-8580765-B2 Nucleoside phosphoramidate prodrugs GILEAD PHARMASSET LLC (US) 2013-11-12 — — US disclosed
US-20130029929-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS GILEAD PHARMASSET LLC (US) 2013-01-31 — — US disclosed
US-8334270-B2 Nucleoside phosphoramidate prodrugs GILEAD PHARMASSET LLC (US) 2012-12-18 — — US disclosed
US-20110257122-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2011-10-20 — — US disclosed
US-20110245484-A1 STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES PHARMASSET, INC. (US) 2011-10-06 — — US disclosed
US-7964580-B2 Nucleoside phosphoramidate prodrugs PHARMASSET, INC. (US) 2011-06-21 — — US disclosed
EP-2203462-A2 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS Pharmasset, Inc. (US) 2010-07-07 — — EP disclosed
US-20100016251-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2010-01-21 — — US disclosed
WO-2008121634-A2 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139227-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885P2RY2 600/4885
US-20100016251-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885P2RY2 600/4885
US-20140045783-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1305/4885CYP2C9 902/4885P2RY2 587/4885
US-20130029929-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885P2RY2 600/4885
US-20110245484-A1 STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES PPA1, ENPP1, ITPA CYP3A4 1919/4885CYP2C9 1843/4885P2RY2 134/4885
US-11642361-B2 Nucleoside phosphoramidate prodrugs PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885P2RY2 600/4885
US-20110257122-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885P2RY2 600/4885
US-20210196741-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885P2RY2 600/4885
US-12121529-B2 Nucleoside phosphoramidate prodrugs PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885P2RY2 600/4885
US-10183037-B2 Nucleoside phosphoramidate prodrugs PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885P2RY2 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.